Low-Dose Liver Radiation with Immunotherapy for Lung Cancer and Melanoma
This study is investigating if adding Low-Dose Liver Radiation (LD-LRT) can improve how well immunotherapy works for people with non-small cell lung cancer or melanoma that has spread to the liver. You would receive LD-LRT the week before your first three cycles of standard immunotherapy treatment. The main goal is to see if this combination increases the time you live without your cancer getting worse (progression-free survival). Researchers are hoping to see a 25% improvement in progression-free survival at 6 months compared to historical results. This study is for adults aged 18 and older who are able to receive standard immunotherapy.
- Study design
- This is an interventional study planning to enroll 21 participants across two groups: one for non-small cell lung cancer and one for melanoma. It is not specified if it is randomized or blinded.
- What's involved
- You would receive Low-Dose Liver Radiation (LD-LRT) the week prior to Cycles 1, 2, and 3 of your standard immunotherapy treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, progression-free survival, is measured at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression free survival (PFS) measured by 6-month PFS for each cohort compared separately to historical trials with an effect size goal of 25% improvement in 6-month PFS6 months
The primary objective is to evaluate whether the addition of Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS) in patients with melanoma and non-small cell lung cancer (NSCLC) with liver metastases receiving immunotherapy. The primary endpoint is 6-month PFS for each cohort compared separately to historical trials with an effect size goal of 25% improvement in 6-month PFS.